Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Hoboken, NJ
Wiley
2013
|
| Ausgabe: | 2. ed. |
| Schlagworte: | |
| Beschreibung: | Includes bibliographical references and index "There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher |
| Beschreibung: | XXXI, 538 S. Ill., graph. Darst. |
| ISBN: | 9781118540299 1118540298 9781118488133 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV041765956 | ||
| 003 | DE-604 | ||
| 005 | 20240328 | ||
| 007 | t | ||
| 008 | 140331s2013 ad|| |||| 00||| eng d | ||
| 020 | |a 9781118540299 |9 978-1-118-54029-9 | ||
| 020 | |a 1118540298 |9 1-118-54029-8 | ||
| 020 | |a 9781118488133 |c hardback |9 978-1-118-48813-3 | ||
| 035 | |a (OCoLC)818316875 | ||
| 035 | |a (DE-599)BVBBV041765956 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-20 |a DE-19 | ||
| 082 | 0 | |a 615/.19 |2 23 | |
| 084 | |a VS 5350 |0 (DE-625)147687:253 |2 rvk | ||
| 100 | 1 | |a Copeland, Robert A. |d 1956- |e Verfasser |0 (DE-588)1055791159 |4 aut | |
| 245 | 1 | 0 | |a Evaluation of enzyme inhibitors in drug discovery |b a guide for medicinal chemists and pharmacologists |c Robert A. Copeland |
| 250 | |a 2. ed. | ||
| 264 | 1 | |a Hoboken, NJ |b Wiley |c 2013 | |
| 300 | |a XXXI, 538 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a "There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher | ||
| 650 | 4 | |a Enzyme Inhibitors / therapeutic use | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Enzyme Inhibitors / chemistry | |
| 650 | 7 | |a MEDICAL / Drug Guides |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Nursing / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacy |2 bisacsh | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Enzyme inhibitors / Therapeutic use / Testing | |
| 650 | 4 | |a Drugs / Design | |
| 650 | 4 | |a Enzyme inhibitors / Structure-activity relationships | |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Enzyminhibitor |0 (DE-588)4152479-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Enzyminhibitor |0 (DE-588)4152479-2 |D s |
| 689 | 0 | 1 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-027212046 | ||
Datensatz im Suchindex
| _version_ | 1804152072717729792 |
|---|---|
| any_adam_object | |
| author | Copeland, Robert A. 1956- |
| author_GND | (DE-588)1055791159 |
| author_facet | Copeland, Robert A. 1956- |
| author_role | aut |
| author_sort | Copeland, Robert A. 1956- |
| author_variant | r a c ra rac |
| building | Verbundindex |
| bvnumber | BV041765956 |
| classification_rvk | VS 5350 |
| ctrlnum | (OCoLC)818316875 (DE-599)BVBBV041765956 |
| dewey-full | 615/.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.19 |
| dewey-search | 615/.19 |
| dewey-sort | 3615 219 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| edition | 2. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03186nam a2200529zc 4500</leader><controlfield tag="001">BV041765956</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240328 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">140331s2013 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118540299</subfield><subfield code="9">978-1-118-54029-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118540298</subfield><subfield code="9">1-118-54029-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118488133</subfield><subfield code="c">hardback</subfield><subfield code="9">978-1-118-48813-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)818316875</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV041765956</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.19</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5350</subfield><subfield code="0">(DE-625)147687:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Copeland, Robert A.</subfield><subfield code="d">1956-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1055791159</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of enzyme inhibitors in drug discovery</subfield><subfield code="b">a guide for medicinal chemists and pharmacologists</subfield><subfield code="c">Robert A. Copeland</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, NJ</subfield><subfield code="b">Wiley</subfield><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXXI, 538 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme Inhibitors / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme Inhibitors / chemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Drug Guides</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Nursing / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacy</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme inhibitors / Therapeutic use / Testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs / Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Enzyme inhibitors / Structure-activity relationships</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-027212046</subfield></datafield></record></collection> |
| id | DE-604.BV041765956 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T01:04:54Z |
| institution | BVB |
| isbn | 9781118540299 1118540298 9781118488133 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-027212046 |
| oclc_num | 818316875 |
| open_access_boolean | |
| owner | DE-20 DE-19 DE-BY-UBM |
| owner_facet | DE-20 DE-19 DE-BY-UBM |
| physical | XXXI, 538 S. Ill., graph. Darst. |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Wiley |
| record_format | marc |
| spelling | Copeland, Robert A. 1956- Verfasser (DE-588)1055791159 aut Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists Robert A. Copeland 2. ed. Hoboken, NJ Wiley 2013 XXXI, 538 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Includes bibliographical references and index "There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher Enzyme Inhibitors / therapeutic use Drug Design Enzyme Inhibitors / chemistry MEDICAL / Drug Guides bisacsh MEDICAL / Nursing / Pharmacology bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh Medizin Enzyme inhibitors / Therapeutic use / Testing Drugs / Design Enzyme inhibitors / Structure-activity relationships Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Enzyminhibitor (DE-588)4152479-2 gnd rswk-swf Enzyminhibitor (DE-588)4152479-2 s Arzneimittelentwicklung (DE-588)4143176-5 s DE-604 |
| spellingShingle | Copeland, Robert A. 1956- Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists Enzyme Inhibitors / therapeutic use Drug Design Enzyme Inhibitors / chemistry MEDICAL / Drug Guides bisacsh MEDICAL / Nursing / Pharmacology bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh Medizin Enzyme inhibitors / Therapeutic use / Testing Drugs / Design Enzyme inhibitors / Structure-activity relationships Arzneimittelentwicklung (DE-588)4143176-5 gnd Enzyminhibitor (DE-588)4152479-2 gnd |
| subject_GND | (DE-588)4143176-5 (DE-588)4152479-2 |
| title | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists |
| title_auth | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists |
| title_exact_search | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists |
| title_full | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists Robert A. Copeland |
| title_fullStr | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists Robert A. Copeland |
| title_full_unstemmed | Evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists Robert A. Copeland |
| title_short | Evaluation of enzyme inhibitors in drug discovery |
| title_sort | evaluation of enzyme inhibitors in drug discovery a guide for medicinal chemists and pharmacologists |
| title_sub | a guide for medicinal chemists and pharmacologists |
| topic | Enzyme Inhibitors / therapeutic use Drug Design Enzyme Inhibitors / chemistry MEDICAL / Drug Guides bisacsh MEDICAL / Nursing / Pharmacology bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh Medizin Enzyme inhibitors / Therapeutic use / Testing Drugs / Design Enzyme inhibitors / Structure-activity relationships Arzneimittelentwicklung (DE-588)4143176-5 gnd Enzyminhibitor (DE-588)4152479-2 gnd |
| topic_facet | Enzyme Inhibitors / therapeutic use Drug Design Enzyme Inhibitors / chemistry MEDICAL / Drug Guides MEDICAL / Nursing / Pharmacology MEDICAL / Pharmacology MEDICAL / Pharmacy Medizin Enzyme inhibitors / Therapeutic use / Testing Drugs / Design Enzyme inhibitors / Structure-activity relationships Arzneimittelentwicklung Enzyminhibitor |
| work_keys_str_mv | AT copelandroberta evaluationofenzymeinhibitorsindrugdiscoveryaguideformedicinalchemistsandpharmacologists |